Recent Quotes (30 days)

You have no recent quotes
chg | %

Acrux Limited  

(Public, ASX:ACR)   Watch this stock  
Find more results for ASX: ACR
0.170
-0.010 (-5.56%)
Oct 23 - Close
ASX data delayed by 20 mins - Disclaimer
Currency in AUD
Range 0.17 - 0.18
52 week 0.14 - 0.36
Open 0.17
Vol / Avg. 187,486.00/462,564.00
Mkt cap 28.31M
P/E 68.55
Div/yield     -
EPS 0.00
Shares 166.52M
Beta     -
Inst. own     -
Oct 26, 2017
Acrux Ltd Annual Shareholders Meeting - 10:00AM GMT+11 - Add to calendar
Oct 25, 2017
Q1 2018 Acrux Ltd Corporate Sales Release Add to calendar
Aug 24, 2017
Preliminary 2017 Acrux Ltd Earnings Call
Aug 22, 2017
Preliminary 2017 Acrux Ltd Earnings Release
Jul 26, 2017
Q4 2017 Acrux Ltd Corporate Sales Release
  

Key stats and ratios

Q2 (Jun '17) 2017
Net profit margin -68.34% -1.02%
Operating margin -90.43% 1.52%
EBITD margin - 52.66%
Return on average assets -24.76% -0.48%
Return on average equity -27.75% -0.55%
Employees 43 -
CDP Score - -

Address

103-113 Stanley St
MELBOURNE, VIC 3003
Australia
+61-3-83790100 (Phone)
+61-3-83790101 (Fax)

Website links

Description

Acrux Limited is a drug development company. The Company is engaged in developing and commercializing branded and generic transdermal and topical pharmaceuticals for global markets. The Company's transdermal or topical pharmaceutical product portfolio can be segregated into approximately two streams, such as generic pharmaceutical products and specialty pharmaceutical products. The Company's products include Axiron, Ellavie, Evamist and Lenzetto. Axiron (testosterone) topical solution CIII is a testosterone topical solution approved for application via an armpit (underarm) applicator. It has developed the estradiol spray for women, used to treat moderate to severe hot flushes commonly associated with menopause. In the United States, the Company's estradiol spray is branded Evamist. The Company has licensed its estradiol product to Gedeon Richter to commercialize in various territories, including Europe and Eurasia. Gedeon Richter has branded the estradiol spray as Lenzetto.

Officers and directors

Michael Kotsanis Chief Executive Officer, Managing Director, Executive Director
Age: 49
Tim Bateman Chief Financial Officer, Company Secretary
Nina Webster Commercial Director
Felicia Colagrande Product Development and Technical Affairs Director
C. O'Sullivan Portfolio Director
Ross Dobinson Non-Executive Chairman of the Board
Geoffrey E. D. Brooke M.D. Non-Executive Independent Director
Age: 60
Simon Green Non-Executive Independent Director
Timothy Charles Oldham Non-Executive Independent Director